Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 841 across all filing types
Latest filing 2013-01-31 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim report, January-December 2012' and contains comprehensive financial statements, including income statements, cash flow data, and detailed management analysis of business operations, development programs, and product portfolios. It is clearly a periodic financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). FY 2012
2013-01-31 English
Orexo enters research agreement with AstraZeneca for respiratory disease program
Regulatory Filings Classification · 1% confidence The document is a press release dated January 25, 2013, announcing that Orexo has entered into a research agreement with AstraZeneca concerning a preclinical program (OX-CLI) for respiratory diseases. This announcement details a strategic partnership, rights transfer options, and potential future milestones/royalties. This type of announcement, which concerns a significant business development, partnership, or transaction that doesn't fit neatly into standard financial reporting (like 10-K, ER, or DIV), is best classified as a general Regulatory Filing (RNS) or potentially a Transaction in Own Shares (POS) if it involved share issuance/repurchase, or M&A Activity (TAR) if it were a merger. Since it is a research agreement/option to acquire assets, it is a significant corporate event announcement. Given the options, RNS serves as the best general regulatory announcement category for non-standard corporate actions, although it is closely related to business development. However, since it is a specific announcement about a business deal/partnership, and not a standard financial report, RNS is the most appropriate fallback for a significant, non-standard corporate event announcement not covered by other specific codes like DIV, ER, or 10-K.
2013-01-25 English
Orexo ingår forskningsavtal med AstraZeneca inom området luftvägssjukdomar
Regulatory Filings Classification · 1% confidence The document is a press release dated January 25, 2013, announcing a research agreement between Orexo and AstraZeneca regarding the OX-CLI program for respiratory diseases. This announcement details a collaboration, potential future licensing, milestone payments, and royalties. This type of announcement, which concerns strategic business development, partnerships, and potential future financing/revenue streams stemming from R&D activities, fits best under 'Capital/Financing Update' (CAP) if it involves significant financial structuring or 'Regulatory Filings' (RNS) as a general corporate announcement. Given the focus on a specific research collaboration agreement that includes potential future acquisition and royalty structures, it is a significant corporate event announcement. Since there is no specific category for 'Research Collaboration Announcement', and it is not a standard financial report (10-K, IR, ER), nor a management change (MANG) or dividend (DIV), it falls under the general regulatory announcement category, RNS, as it is a material event disclosed to the market. However, looking closely at the definitions, 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes.' While this is a research deal, the structure involves future payments and potential acquisition, which touches upon financing/value creation. Given the nature of the announcement (a material corporate event disclosure), RNS is the most appropriate general catch-all for non-standard material news. If the deal involved immediate capital raising, CAP would be better. Sticking to the most general fit for material, non-standard news: RNS.
2013-01-25 Swedish
Antal aktier och röster i Orexo
Share Issue/Capital Change Classification · 1% confidence The document is a short press release dated December 28, 2012, announcing a change in the total number of shares and votes in the company due to the exercise of stock options. This directly relates to the company's capital structure and share count. This fits the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). The length is very short, but the content is a direct notification of a capital structure event, making SHA more specific than the general fallback (RNS).
2012-12-28 Swedish
Number of shares and votes in Orexo
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release dated December 28, 2012, announcing a change in the total number of shares and votes due to the exercise of warrants. This directly relates to a change in the company's capital structure (share count). This aligns best with the 'Share Issue/Capital Change' definition (SHA), which covers changes in the number of shares outstanding. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a dividend notice (DIV) or director dealing (DIRS). Given the short length and specific topic, SHA is the most appropriate classification.
2012-12-28 English
Orexo provides US commercialization progress update and direction for 2013 financial outlook
Earnings Release Classification · 1% confidence The document is titled as a "Press release" dated December 19th, 2012, providing an update on US commercialization progress, partnership strategy for Zubsolv™ and Abstral®, FDA trade name acceptance, and a financial outlook projecting profitability in late 2013. It also mentions a letter sent to shareholders on the same date. This content—a forward-looking business update, strategic decisions, and financial projections released via press release—is characteristic of an Earnings Release (ER) or a general business update. Since it provides key financial direction ('project it will turn profitable in late 2013') but is not the full, detailed quarterly report (IR) or the official annual report (10-K), ER is the most appropriate classification. It is not a transcript (CT), a formal audit report (AR), or a proxy statement (PSI). FY 2013
2012-12-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.